Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast...

Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant...

Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )

OncoAlert and ecancer - ESMO 2021 preview

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 preview ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Multidisciplinary management of ovarian germ cell tumours - a single...

Dr Sandip Ganguly - Tata Medical Center, Kolkata, India

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA...

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

$Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )$

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma...

Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )

More from ecancer